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Introduction: Lower angiotensin-converting enzyme (ACE) activity could increase the risk of Alzheimer’s disease
(AD) as ACE functions to degrade amyloid-β (Aβ). Therefore, we investigated whether ACE protein and activity levels
in cerebrospinal fluid (CSF) and serum were associated with CSF Aβ, total tau (tau) and tau phosphorylated at
threonine 181 (ptau).
Methods: We included 118 subjects from our memory clinic-based Amsterdam Dementia Cohort (mean age 66 ± 8 years)
with subjective memory complaints (n = 40) or AD (n = 78), who did not use antihypertensive drugs. We measured ACE
protein levels (ng/ml) and activity (RFU) in CSF and serum, and amyloid β1–42, tau and ptau (pg/ml) in CSF.
Results: Cross-sectional regression analyses showed that ACE protein level and activity in CSF and serum were lower in
patients with AD compared to controls. Lower CSF ACE protein level, and to a lesser extent serum ACE protein level and
CSF ACE activity, were associated with lower CSF Aβ, indicating more brain Aβ pathology; adjusted regression coefficients
(B) (95% CI) per SD increase were 0.09 (0.04; 0.15), 0.06 (0.00; 0.12) and 0.05 (0.00; 0.11), respectively. Further, lower CSF ACE
protein level was associated with lower CSF tau and ptau levels; adjusted B’s (95% CI) per SD increase were 0.15
(0.06; 0.25) and 0.17 (0.10; 0.25), respectively.
Conclusions: These results strengthen the hypothesis that ACE degrades Aβ. This could suggest that lowering ACE levels
by for example ACE-inhibitors might have adverse consequences for patients with, or at risk for AD.Introduction
Alzheimer’s disease (AD) is characterized by the accu-
mulation of extracellular amyloid-beta (Aβ) plaques and
intracellular neurofibrillary tangles (tau pathology), which
are reflected by lower Aβ, and higher total tau (tau) and tau
phosphorylated at threonine 181 (ptau) in cerebrospinal
fluid (CSF) [1].
In the last decade, the role of the renin–angiotensin
system (RAS) in the etiology of AD has received increas-
ing attention. Inheritance of the I-allele – associated with
lower plasma angiotensin-converting enzyme (ACE) levels
[2] – was related to increased risk of AD [3,4], although
these findings have not been supported by recent genome-
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article, unless otherwise stated.[7]. Further, in vitro studies showed that ACE functions to
degrade Aβ, and administration of ACE inhibitors pro-
moted the accumulation of Aβ [8-10], while in vivo studies
on various mouse models of AD showed indirect
evidence that ACE can degrade Aβ (reviewed in [11]).
Together, these data suggest that ACE is important for
Aβ degradation, and hence low ACE activity can lead
to increased Aβ-mediated neuronal damage, plaque ac-
cumulation, and risk of AD [12].
Few studies have examined the association between
ACE and AD biomarkers in CSF [13,14]. Results on the
association between the I-allele, or haplotypes, of the ACE
gene, which have been associated with lower ACE levels,
and CSF Aβ were inconclusive [13,14]. Further, one small-
scale study found that administration of an ACE inhibitor
did not influence AD biomarkers in CSF [15].
The current literature almost entirely comes from
laboratory-based and genetic association studies. How-
ever, the laboratory-based studies are not comparable
with the human disease state and the findings fromtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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disequilibrium with the true risk factor [3]. Examining
direct measures of ACE (such as serum or CSF ACE) in
relation to CSF AD biomarkers might therefore be more
clinically meaningful – especially since the widely pre-
scribed antihypertensive ACE-inhibitors strongly inhibit
ACE activity [16], thereby possibly not only reducing
the unfavorable angiotensin (ANG)I to ANGII conver-
sion, but also the favorable Aβ degradation.
The aim of the current study was to investigate the
association of serum and CSF ACE protein levels and
activity with CSF AD biomarkers – Aβ, tau and ptau –
in a memory clinic cohort. It has increasingly been rec-
ognized that nearly all organs of the body have their
own local paracrine-like RAS, with organ-specific functions
[17]. The brain also has its own RAS system, acting largely
independent of the peripheral RAS [17]. We therefore
hypothesize that CSF and serum ACE reflect the activity
in the brain RAS and peripheral RAS, respectively, and
that CSF ACE activity and, to a lesser extent, serum
ACE activity are associated with lower CSF Aβ, indicating
worse Aβ-related pathology in the brain.
Methods
Study population
Patients were included from the memory clinic-based
Amsterdam Dementia Cohort of the Alzheimer Center
of the VU University Medical Center (VUMC). They
underwent standard dementia screening including phys-
ical and neurological examination, as well as laboratory
tests, electroencephalography, brain magnetic resonance
imaging and comprehensive neuropsychological testing.
The diagnosis of probable AD was made according to the
National Institute of Neurological Disorders and Stroke–
Alzheimer’s Disease and Related Disorders Association
criteria [18] by consensus of a multidisciplinary team,
without knowledge of CSF results and the apolipoprotein
E (APOE) genotype. When the results of all examinations
were normal, patients were considered to have subjective
complaints (that is, criteria for mild cognitive impairment
not fulfilled). Diabetes mellitus and hypercholesterolemia
were defined based on self-reported medical history and
medication use. Blood pressure was measured manually in
a standardized manner using a sphygmomanometer with
the patient in a sitting position after 5 minutes of rest.
The level of education was classified using the seven-point
rating scale of Verhage ranging from 1 (low, elementary
school not completed) to 7 (high, university).
For the current study, patients using antihypertensive
drugs were excluded, because some of these drugs strongly
influence ACE levels [19]. Of the patients aged 50 to
80 years old with available CSF, we included 40 persons
with subjective complaints (control group) and 78 persons
with AD (AD group). The ethical review board of theVUMC approved the study and all subjects gave written
informed consent.
Sampling of blood and cerebrospinal fluid
A blood sample was taken, and after half an hour of
clotting the samples were spun at 1,800 × g for 10 minutes
at 4°C, then aliquoted into Sarstedt polypropylene cryovials
and immediately stored at −80°C until further analyses.
CSF was obtained by lumbar puncture between the L3/L4
or the L4/L5 intervertebral space, using a 25-gauge needle,
and collected in 10 ml polypropylene tubes. Within two
hours, 2 ml of CSF samples were centrifuged at 1,800 × g
for 10 minutes at 4°C and stored at −20°C for analysis of
CSF biomarkers within 2 months (see below). The remain-
der of the CSF was aliquoted in polypropylene tubes of 0.5
or 1 ml, and stored at −80°C until further analysis [20].
APOE and Alzheimer’s disease cerebrospinal fluid
biomarkers
DNA was isolated from 10 ml ethylenediamine tetraace-
tic acid blood and the APOE genotype was determined
using the Light Cycler APOE mutation detection method
(Roche Diagnostics GmbH, Mannheim, Germany).
CSF Aβ1–42, tau, and ptau were measured by commer-
cially available ELISAs (Innotest -β-amyloid(1-42), Innotest
hTAU-Ag 168 and Innotest Phosphotau(181P); Innogenetics,
Ghent, 169 Belgium). The performance of the assays was
monitored with internal quality controls consisting of pools
of surplus CSF specimens. In the study period, multiple in-
ternal quality controls with various concentrations have
been used. The interassay coefficient of variation (CV)
(mean ± standard deviation) was 11.3 ± 4.9% for Aβ, 9.3 ±
1.5% for tau, and 9.4 ± 2.5% for ptau [21].
Angiotensin-converting enzyme protein assays
A commercially available sandwich enzyme-linked immuno-
sorbent assay (R&D Systems, Abingdon, UK) was used ac-
cording to the manufacturer’s guidelines to measure the
ACE concentration in CSF and serum, as described previ-
ously [22]. Absorbance was read at 450 nm on a FLUOstar
OPTIMA plate reader (BMG Labtech, Aylesbury, Bucking-
hamshire, UK). The samples were analyzed in duplicate, and
ACE concentrations were interpolated from the standard
curves of known concentrations of recombinant human
ACE (929-ZN; R&D Systems). The ACE inhibitor captopril
was purchased from Enzo Life Sciences (Exeter, UK). The
interassay CV (mean ± standard deviation) was 8.7 ± 8.9%
for CSF ACE and 13.0 ± 7.0% for serum ACE. The intra-
assay CV was 7.9 ± 6.5% for CSF ACE and 7.6 ± 5.6% for
serum ACE.
Angiotensin-converting enzyme activity assays
Monoclonal anti-human ACE antibody (MAB929), re-
combinant human ACE (929-ZN) and the internally







Age (years) 63 (8) 68 (7)**
Female sex (%) 47 64*
Education (range 1 to 7) 6 (3 to 7) 5 (3 to 6)
APOE-ε4 carrier (%) 23 66*
MMSE (range 0 to 30) 28 (26 to 30) 22 (16 to 27)*
Vascular risk factors/disease
Smoking (% current) 23 23
Body mass index (kg/m2) 25 (5) 24 (5)
Diabetes mellitus (%) 14 14
Hypercholesterolemia (%) 28 22*
Blood pressure measures
Systolic (mmHg) 133 (14) 147 (22)**
Diastolic (mmHg) 83 (9) 86 (13)**
Hypertension (%) 30 55*
ACE measures
CSF ACE protein level (ng/ml) 3.78 (1.30) 3.56 (1.16)**
CSF ACE activity (RFU) 155 (61) 148 (58)*
Serum ACE protein level (ng/ml) 4.22 (1.50) 3.72 (1.14)**
Serum ACE activity (RFU) 255 (152) 205 (116)**
CSF biomarkers
Amyloid β1–42 (pg/ml) 887 (622
to 1,157)
475 (334 to 743)**
Total tau (pg/ml) 246 (122 to 371) 619 (344 to 1,102)**
Phosphorylated tau (pg/ml) 45 (29 to 74) 87 (54 to 137)**
Data presented as mean (standard deviation), percentage, or median (10th to
90th percentile). Percentage of missing values before imputation: education,
0.8%; APOE genotyping, serum ACE protein and activity levels, 1.7%; MMSE,
3.4%; smoking, 7.6%; diabetes mellitus and hypercholesterolemia, 14%; all
other variables, 0%. ACE, angiotensin-converting enzyme; AD, Alzheimer’s
disease; APOE, apolipoprotein E; CSF, cerebrospinal fluid; MMSE: Mini-Mental
State Examination; RFU, relative fluorescence units.
*P < 0.05 versus controls, **P < 0.01 versus controls.
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(Dnp)-OH; ES005) were purchased from R&D Systems
and were used to optimize an immunocapture-based
fluorogenic assay for measurement of ACE activity in
CSF and serum (see also Additional file 1) based on the
method previously used by Miners and colleagues [23].
Fluorescence was measured by excitation at 320 nm
and emission at 405 nm, in a FLUOstar OPTIMA plate
reader. The mean fluorescence of the negative controls
was subtracted from standard and sample readings, as was
done for the fluorescence of the ACE-specific captopril-
inhibited well. The ACE-specific inhibitor captopril inhib-
ited ACE activity by more than 90%. Each sample was
measured in duplicate and the mean fluorescence of ACE
activity was calculated, based on the standard curve of re-
combinant ACE. The interassay CV (mean ± standard devi-
ation) was 8.5 ± 8.4% for CSF ACE and 8.1 ± 8.7% for
serum ACE. The intra-assay CV was 8.7 ± 5.9% for CSF
ACE and 9.1 ± 8.5% for serum ACE.
Data analyses
We used multiple imputation (10 datasets) to address
missing values (see Table 1), and data were analyzed using
SPSS version 20.0 (Chicago, IL, USA), by pooling the 10
imputed datasets [24,25].
First, patient characteristics were calculated for
separate study groups (control group and AD group)
and differences were evaluated by analysis of vari-
ance for continuous variables, or by Fisher’s exact
test for categorical variables. Second, Pearson’s cor-
relation coefficients between ACE protein and activ-
ity levels for each of CSF and serum in turn were
examined. Pearson’s correlation coefficients between
Aβ and tau or ptau were also analyzed. Third, we
examined the linear regression between APOE-ε4 al-
lele and Aβ, tau and ptau (Model 2). Fourth, linear
regression analysis was used to investigate the
associations of ACE measures (continuous) with log-
transformed CSF biomarker levels of Aβ, tau and
ptau (continuous), unadjusted (Model 1) and ad-
justed for age, sex and study groups (Model 2). Since
inheritance of the AD risk-associated APOE-ε4 allele
and vascular risk factors including blood pressure
measures could influence the association between
ACE measures and CSF biomarkers, we additionally
adjusted for APOE-ε4 (carrier vs. noncarrier) and vascu-
lar risk factors (systolic blood pressure, diastolic blood
pressure, body mass index, smoking, history of hyper-
cholesterolemia or diabetes mellitus) (Model 3). Finally,
analysis of covariance was used to estimate the adjusted
mean log-transformed CSF Aβ, tau and ptau levels across
tertiles of ACE measures within the separate study
groups. For graphical purposes, the log-transformed
values were back transformed.Results
In the total population of 118 subjects, the mean age
was 66 (standard deviation, range: 8, 50 to 79) years and
52% were female. Table 1 shows that patients in the
AD group were older, more often female, and more
often APOE-ε4 carriers than patients in the control
group. They also had less hyperlipidemia and higher
blood pressure levels. CSF Aβ levels were lower in AD
patients, and CSF tau and ptau levels were higher in
AD patients. Further, all ACE measures were lower in
patients with AD compared with patients in the control
group (Table 1). The Pearson correlation coefficient
between CSF ACE protein level and CSF ACE activity was
0.26 (P = 0.005), between serum ACE protein level and
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serum ACE protein levels was 0.54 (P < 0.001), and between
CSF and serum ACE activity levels was 0.07 (P = 0.494).
The correlation between tau and Aβ was −0.43 (P < 0.001)
and between ptau and Aβ was −0.41 (P = 0.0004). Further,
APOE-ε4 carriers had significantly lower Aβ (Β =−0.32),
and significantly higher tau (Β = 0.50) and ptau levels
(Β = 0.31); P < 0.001 for all.Cerebrospinal fluid ACE measures and cerebrospinal
fluid biomarkers
In the total population, higher CSF ACE protein level was
independently associated with higher CSF Aβ, tau and
ptau levels (Table 2). When stratified by study group, the
associations between higher CSF ACE protein levels and
higher CSF Aβ, tau and ptau were present in the control
group and the AD group, although significance was lost
for CSF tau in the control group (Figures 1, 2 and 3).
Higher CSF ACE activity was also marginally associated
with higher CSF Aβ levels, but not with CSF tau or ptau
levels (Table 2). When stratified by study groups, the asso-
ciation was particularly present in the AD group (Figure 1).Serum ACE measures and cerebrospinal fluid biomarkers
In the total population, higher serum ACE protein level
was associated with higher CSF Aβ (borderline signifi-
cance), but not with CSF tau or ptau levels (Table 2). When
stratified by study groups, the association was more evident
in the control group and not in the AD group: mean differ-
ences (95% confidence interval) between the highest andTable 2 Linear regression analyses between CSF and serum A
total population (n = 118)
Model Ln Aβ42
CSF ACE protein levela 1 0.12 (0.05; 0.
2 0.09 (0.04; 0.
3 0.11 (0.05; 0.
CSF ACE activityb 1 0.07 (−0.00;
2 0.05 (−0.00;
3 0.06 (0.00; 0
Serum ACE protein levelc 1 0.09 (0.02; 0
2 0.06 (−0.00;
3 0.04 (−0.02;
Serum ACE activityd 1 0.06 (−0.01;
2 0.03 (−0.03;
3 0.02 (−0.04;
Data presented as Β (95% confidence interval). Model 1: unadjusted. Model 2: adjus
genotype, systolic blood pressure, diastolic blood pressure, body mass index, smok
ACE, angiotensin-converting enzyme; CSF, cerebrospinal fluid; Ln, log-transformed;
tau, total tau. *P < 0.05, **P < 0.01. aPer standard deviation increase (1.32 ng/ml). bPe
(1.30 ng/ml). dPer standard deviation increase (133 RFU).lowest serum ACE protein tertiles were 193 (47; 340)
and 44 (−62; 151), respectively (Model 2).
Serum ACE activity was not associated with higher
CSF Aβ, tau or ptau levels (Table 2).Discussion
The main findings of this study are that lower CSF ACE
protein levels, and to a lesser extent serum ACE protein
and CSF ACE activity levels, were associated with lower
CSF Aβ levels, indicating increased Aβ accumulation in
the brain. Surprisingly, lower CSF ACE protein levels were
associated with lower CSF tau and ptau levels, indicating
less brain tau pathology. These associations were found in
both control and AD patients and were independent of
age, sex, APOE genotype, and vascular risk factors. Fur-
ther, CSF and serum ACE protein and activity levels were
lower in AD patients compared with controls.
To our knowledge, this is the first study that linked
direct measures of ACE activity to the CSF AD bio-
markers Aβ, tau, and ptau. Our results on the associ-
ation of CSF ACE protein level and CSF Aβ are in line
with studies that showed an association between the
ACE gene and Aβ. Haplotypes of the ACE gene that
were associated with lower ACE levels were related to
lower CSF Aβ [13,14], and another study showed that
the I-allele (indicating lower ACE levels) was associ-
ated with slightly more Aβ load in the brain at autopsy
[26]. The Rotterdam study examined the ACE genotype
in relation to brain atrophy (which is associated with
increased brain Aβ plaques) [1], and found that female
I/I genotype carriers had smaller hippocampal andCE measures and log-transformed CSF biomarkers in the
Ln tau Ln ptau
19)** 0.10 (−0.01; 0.22) 0.14 (0.05; 0.22)**
15)** 0.15 (0.06; 0.25)** 0.17 (0.10; 0.25)**
16)** 0.16 (0.05; 0.26)** 0.19 (0.10; 0.27)**
0.14) −0.06 (−0.18; 0.06) 0.02 (−0.07; 0.11)
0.11) −0.03 (−0.13; 0.07) 0.04 (−0.04; 0.12)
.11)* −0.04 (−0.14; 0.06) 0.03 (−0.05; 0.11)
.17)* −0.09 (−0.21; 0.03) −0.02 (−0.11; 0.07)
0.12) −0.03 (−0.13; 0.07) 0.02 (−0.06; 0.10)
0.11) −0.04 (−0.15; 0.06) 0.02 (−0.06; 0.11)
0.14) −0.10 (−0.22; 0.01) −0.02 (−0.10; 0.07)
0.09) −0.05 (−0.15; 0.05) 0.02 (−0.06; 0.10)
0.08) −0.06 (−0.17; 0.05) 0.01 (−0.08; 0.10)
ted for age, sex and study groups. Model 3: additionally adjusted for APOE-ε4
ing, history of hypercholesterolemia and diabetes mellitus. Aβ, amyloid-beta;
ptau, tau phosphorylated at threonine 181; RFU, relative fluorescence units;
r standard deviation increase (59 RFU). cPer standard deviation increase
Figure 1 Angiotensin-converting enzyme measures and cerebrospinal fluid amyloid-β1–42. Mean (standard error) in cerebrospinal fluid
(CSF) amyloid-β1–42 across tertiles of CSF angiotensin-converting enzyme (ACE) activity and CSF ACE protein level, in the control group (A) and
the demented group (B). Analyses were adjusted for age and sex. Tertiles for CSF ACE activity: <121.66; 121.66 to 177.56; >177.56 relative
fluorescence units. Tertiles for CSF ACE protein level: <2.95; 2.95 to 3.92; >3.92 ng/ml. *P < 0.05.
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SMART-MR study that lower serum ACE levels were
associated with more progression of cortical brain at-
rophy [28]. Together, these data suggest that lower
ACE could lead to more Aβ accumulation in the brain,reflected by lower CSF Aβ, and support previous re-
ports that higher ACE levels, through degradation of
Aβ, may contribute to less accumulation of Aβ into se-
nile plaques in the brain and subsequently be beneficial
for the occurrence of brain atrophy.
Figure 2 Angiotensin-converting enzyme measures and cerebrospinal fluid total tau. Mean (standard error) in total tau across tertiles of
cerebrospinal fluid (CSF) angiotensin-converting enzyme (ACE) activity and CSF ACE protein level, in the control group (A) and demented group (B).
Analyses were adjusted for age and sex. Tertiles for CSF ACE activity: <121.66; 121.66 to 177.56; >177.56 relative fluorescence units. Tertiles for CSF ACE
protein level: <2.95; 2.95 to 3.92; >3.92 ng/ml. **P < 0.01.
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CSF ACE protein level was associated with lower CSF tau
and ptau. A previous study relating the ACE genotype to
tau load in the brain found no association [26]. The mech-
anisms explaining the relation between lower ACE and
lower CSF tau levels remain largely unknown, although a
role for ANGII could be suggested. A recent study showedthat central infusion of ANGII in normal rat brains in-
duced tau phosphorylation in a dose-dependent manner
via activating glycogen synthase kinase 3β. Furthermore,
this was reversed by co-administration of the ANG II type
1 receptor antagonist, losartan, which is commonly
prescribed for the treatment of hypertension [29]. Our
findings suggest that higher ACE levels which lead to
Figure 3 Angiotensin-converting enzyme measures and cerebrospinal fluid phosphorylated tau. Mean (standard error) in phosphorylated
tau across tertiles of cerebrospinal fluid (CSF) angiotensin-converting enzyme (ACE) activity and CSF ACE protein level, in the control group (A)
and the demented group (B). Analyses were adjusted for age and sex. Tertiles for CSF ACE activity: <121.66; 121.66 to 177.56; >177.56 relative
fluorescence units. Tertiles for CSF ACE protein level: <2.95; 2.95 to 3.92; >3.92 ng/ml. **P < 0.01.
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brain, and in turn result in higher tau levels in the CSF.
Coincidentally, and perhaps ironically, while such elevationsin ACE may exacerbate tau-related pathology, these same
elevations may also have a slightly beneficial mitigating
effect in terms of reducing Aβ pathology. Yet no
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ACE activity, which we might expect to be a more bio-
logically meaningful measure of the likely production of
ANGII from its precursor ANGI [17].
CSF ACE levels were more strongly associated with
AD biomarkers than serum ACE levels. This indicates
that CSF ACE, as might be expected, could reflect the
activity of the brain RAS, thereby showing stronger as-
sociations with brain pathology. Further, ACE protein
levels were more strongly associated with AD biomarkers
than ACE activity levels. Whereas protein levels indicate
the concentration of ACE in body fluid, activity levels par-
ticularly indicate the ANGI to ANGII conversion capacity
of the enzyme [22]. One might thus have expected that
ACE activity levels in particular would be more indicative
of and relevant to Aβ degradation, and would therefore
be more strongly associated with CSF Aβ. At present
we cannot explain this apparent inconsistency; it could
be partly related to the ACE genotype although the
genetic contribution to ACE levels has only been shown
to be relatively modest [12], and unfortunately we did not
have information on the ACE genotype in our population
so we could not explore this. Another reason might be
differential levels of post-translational modification in
the various physiological compartments from which
the samples were derived. ACE activity, and its pro-
posed conversion of Aβ, has been shown previously to
be modulated by post-translational modification [30].
In both CSF and serum there may therefore be differ-
ential levels of glycosylation that can explain the lower
than expected correlations of activity with some of our
outcome measures. Miners and colleagues previously
showed a trend of divergence between ACE levels and
activity in postmortem CSF, but this was not significant
and the patterns observed may have been an artifact of
postmortem delay where additional changes to the
ACE may have occurred post mortem [22]. Yet here re-
mains the possibility that in the brain, from which the
levels of Aβ, tau and ptau emanate, levels of ACE activ-
ity are influenced in a more disease-specific manner by
advancing pathology than occurs in the more periph-
eral compartments we have tested. Indeed, Miners and
colleagues have shown in postmortem brain tissue
from AD patients that their ACE activity and not their
ACE levels are more markedly different than in the
control group [22]. Similarly, according to our data
there is some support that disease-specific modifica-
tions of ACE may be involved since the apparent dis-
crepant findings between ACE levels and activity with
respect to CSF Aβ were less marked and seemed to
correlate more in the AD group (Figure 1B).
Among the strengths of the current study is the use of
CSF ACE measures and CSF biomarkers, which gives
the opportunity to examine during life the associationbetween ACE and AD pathology, without potential con-
founding from postmortem delays. Second, we had
paired CSF and serum samples for all of the patients.
Finally, all patients were assessed in a standardized way
and diagnosed according to commonly used criteria [18].
One of the limitations of our study is the relatively
small study population. Yet the interesting results recom-
mend replication in a larger study sample. Another limita-
tion is the cross-sectional design that prohibits conclusions
on cause or effect. Similarly, we cannot ascertain whether
lower CSF ACE protein and activity levels cause brain Aβ
pathology. However, because we found that the associations
were also present in the control group, it is reasonable to
assume that the downregulation of CSF ACE is not path-
ology driven, and that lower ACE levels might precede the
pathology or alternatively are a general phenomenon asso-
ciated with neurodegeneration. This hypothesis remains to
be further investigated in a larger, longitudinal study.
This study has important clinical implications. If ACE
in the brain does prevent Aβ accumulation in living
humans, our data support the suggestions that taking ACE
inhibitors as antihypertensive drugs, particularly those that
can cross the blood–brain barrier, might compromise Aβ
degradation [31]. Fortunately, while uncertainty remains on
this issue, angiotensin-receptor blockers, which solely target
ANG II effects whilst not interfering directly with ACE,
could provide an immediate and readily available potential
alternative anti-hypertensive therapy for patients at risk for
AD [31-33].Conclusion
We found in a memory clinic cohort that lower CSF
ACE levels were associated with lower CSF Aβ levels,
which suggests more accumulation of Aβ in the brain.
This observation lends support to the hypothesis that
ACE can degrade Aβ, thereby contributing to limiting its
accumulation and possibly to the development or rate of
progression of AD.Additional file
Additional file 1: Is a description of the ACE activity assays.Abbreviations
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